Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
P/E ratio for Nevro Corp. (NVRO)
P/E ratio as of 2023: -8.40
According to Nevro Corp.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.40. At the end of 2022 the company had a P/E ratio of 466.04.
P/E ratio history for Nevro Corp. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -8.40 |
| 2022 | 466.04 |
| 2021 | -21.49 |
| 2020 | -70.18 |
| 2019 | -34.92 |
| 2018 | -23.75 |
| 2017 | -55.42 |
| 2016 | -65.13 |
| 2015 | -26.61 |
| 2014 | -5.60 |
| 2013 | -0.66 |
| 2012 | -0.90 |